ArticleJournal of hematology & oncology2021
Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML.
Open access · goldAbstract read
In one paragraph
Article in Journal of hematology & oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis.Journal of healthcare engineering · 2022Pooled it
- Inflammation as a central driver in AML pathogenesis and therapy resistance.Science China. Life sciences · 2026Review
- Review
- Loss of endothelial miR-126 drives age-related decline in hematopoiesis.Haematologica · 2026Article
- Allosteric inhibition of RAN decreases miR-126 biogenesis in endothelial cells and controls acute myeloid leukemia growth.Communications biology · 2026Article
- Overcoming vascular niche-mediated TKI resistance in acute myeloid leukemia through miR-126 inhibition.NPJ systems biology and applications · 2026Article
- The tumor microenvironment in leukemia: molecular pathways of immune evasion.Frontiers in immunology · 2026Review
- Arteriolar angiogenesis: implications in anti-angiogenic immunotherapy for pancreatic cancers.Cytokine & growth factor reviews · 2025Review
- MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia.Journal of hematology & oncology · 2025Article
- Epigenetic‑ncRNA crosstalk in atherosclerosis: Mechanisms, disease progression and therapeutic potential (Review).International journal of molecular medicine · 2025Review
- The roles of non-coding RNAs (ncRNAs) in the function of leukemic stem cells (LSCs): a comprehensive review.Discover oncology · 2025Review
- Functions, mechanisms, and therapeutic implications of noncoding RNA in acute myeloid leukemia.Fundamental research · 2025Review
- The role of YTHDF2 in anti-tumor immunity.Cell investigation · 2025Article
- Advances in the application of patient-derived xenograft models in acute leukemia resistance.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia.Leukemia · 2025Review
- Leukemia circulation kinetics revealed through blood exchange method.Communications biology · 2024Article
- Signaling pathways governing the behaviors of leukemia stem cells.Genes & diseases · 2024Review
- Understanding the interaction between leukaemia stem cells and their microenvironment to improve therapeutic approaches.British journal of pharmacology · 2024Review
- RNA mGenes & diseases · 2024Article
- Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 9 institutions in 3 countries.
Bin Zhang *Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA. bzhang@coh.org.
Le Xuan Truong Nguyen *Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Dandan Zhao *Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
David E FrankhouserDepartment of Population Science, City of Hope, Duarte, CA, USA.
Huafeng WangDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Dinh Hoa HoangDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Junjing QiaoDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Christina AbundisDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Matthew BrehoveDepartment of Molecular Medicine, City of Hope, Duarte, CA, USA.
Yu-Lin SuDepartment of Immuno-Oncology, City of Hope, Duarte, CA, USA.
Yuxin FengDivision of Experimental Hematology and Cancer Biology, Children's Hospital Medical Center, Cincinnati, OH, USA.
Anthony SteinDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Lucy GhodaDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Adrianne DorranceThe Ohio State University, Columbus, OH, USA.
Danilo PerrottiUniversity of Maryland, Baltimore, MD, USA.
Zhen ChenDepartment of Diabetes Complications and Metabolism, City of Hope, Duarte, CA, USA.
Anjia HanDepartment of Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Flavia PichiorriDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Jie JinDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Tijana Jovanovic-TalismanDepartment of Molecular Medicine, City of Hope, Duarte, CA, USA.
Michael A CaligiuriDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Calvin J KuoDepartment of Medicine, Division of Hematology, Stanford University, Stanford, CA, USA.
Akihiko YoshimuraDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Ling LiDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Russell C RockneDivision of Mathematical Oncology, Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, USA.
Marcin KortylewskiDepartment of Immuno-Oncology, City of Hope, Duarte, CA, USA.
Yi ZhengDivision of Experimental Hematology and Cancer Biology, Children's Hospital Medical Center, Cincinnati, OH, USA.
Nadia CarlessoDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Ya-Huei KuoDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Guido MarcucciDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, 1500 E Duarte Road, Duarte, CA, 91010, USA. gmarcucci@coh.org.ORCID 0000-0002-3983-5908
City of Hope · USCity Of Hope National Medical Center · USCincinnati Children's Hospital Medical Center · USSun Yat-sen University · CNKeio University · JPStanford University · USThe Ohio State University · USUniversity of Maryland, Baltimore · USZhejiang University · CN
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MTargeting MicroRNAs to Eradicate Leukemia Stem CellsR01CA205247 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI KUO, YA-HUEI, MARCUCCI, GUIDO · 2017 to 2025
$4.8MBiologic and Therapeutic Significance of miR-155 in AMLR01CA201184 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CROCE, CARLO M, GARZON, RAMIRO · 2016 to 2020
$2.7MVascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?R01CA248475 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI MARCUCCI, GUIDO, ZHANG, BIN · 2020 to 2024
$2.5MInflammation as determinant of clonal selection in MPN progressionR01HL141379 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CARLESSO, NADIA · 2018 to 2021
$2.1MTargeting Transcriptional Regulators for Immunotherapy of Acute Myeloid LeukemiaR01CA213131 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI KORTYLEWSKI, MARCIN · 2017 to 2021
$2.1MCancer Metabolism Training ProgramT32CA221709 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI David K. Ann, Victoria L. Seewaldt · 2018 to 2026
$1.8MNCI NIH HHS P30 CA033572NCI NIH HHS R01 CA201184NCI NIH HHS R01 CA205247NCI NIH HHS R01 CA213131NCI NIH HHS R01 CA248475NCI NIH HHS T32 CA221709NHLBI NIH HHS R01 HL141379
Abstract
backgroundDuring acute myeloid leukemia (AML) growth, the bone marrow (BM) niche acquires significant vascular changes that can be offset by therapeutic blast cytoreduction. The molecular mechanisms of this vascular plasticity remain to be fully elucidated. Herein, we report on the changes that occur in the vascular compartment of the FLT3-ITD+ AML BM niche pre and post treatment and their impact on leukemic stem cells (LSCs).
methodsBM vasculature was evaluated in FLT3-ITD+ AML models (Mll
resultsIn the normal BM niche, CD31
conclusionsTreatment-induced CD31
Indexed as
Gene Expression Regulation, LeukemicAnimalsBone Marrowfms-Like Tyrosine Kinase 3HumansLeukemia, Myeloid, AcuteMiceMice, Inbred C57BLMicroRNAsNeoplastic Stem CellsUp-RegulationFLT3 protein, humanfms-Like Tyrosine Kinase 3MicroRNAsMIRN126 microRNA, humanMIRN126 microRNA, mouseAcute myeloid leukemiaBM vascular nicheLeukemic stem cellmiR-126TNFαTreatment resistance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.